Infos für
Direkt zu
Fakultäten
Nina Hanke
Forschungsgebiet
Physiologie-basierte Pharmakokinetik (PBPK) Modellierung von Arzneistoff-Wechselwirkungen
Lebenslauf
Seit 06/2014: Postdoktorandin Klinische Pharmazie, Universität des Saarlandes
09/2011 – 05/2014: Laboratory Head Biochemistry, ElexoPharm GmbH
02/2010 – 08/2011: Scientific Expert In Vitro Pharmacology, Abbott Products GmbH
06/2005 – 01/2010: Postdoktorandin Humanphysiologie, Medizinische Hochschule Hannover
10/2001 – 06/2005: Promotion Humanphysiologie, Medizinische Hochschule Hannover
10/1996 – 10/2001: Studium Biochemie, Leibniz Universität Hannover
06/1996: Abitur, Ricarda-Huch-Gymnasium Hannover
Publikationen
Vorträge
Hanke N. PBPK modeling of renally impaired patients. 5th German Pharm-Tox Summit 2020, Leipzig, Germany.
Hanke N. Physiologically-based pharmacokinetic modeling of metformin as a
PMAT/OCT1/OCT2/MATE transporter drug-drug interaction victim drug. 10th International DDI Workshop 2019, Marbach Castle, Germany.
Hanke N. Physiologically-based pharmacokinetic (PBPK) modeling of the chemotherapeutic zoptarelin doxorubicin and model application for drug-drug interaction (DDI) potential analysis. CESAR Annual Meeting 2018, Berlin, Germany.
Hanke N. Physiologically-based pharmacokinetic modeling of drug-drug interactions: rifampin, midazolam and digoxin. 7th International DDI Workshop 2016, Marbach Castle, Germany.
Manuskripte
Fuhr LM, Hanke N, Meibohm B, Lehr T. Effective removal of dabigatran by idarucizumab or hemodialysis: a physiologically based pharmacokinetic modeling analysis. Clin Pharmacokinet 2020;Epub:10.1007/s40262-019-00857-y.
Türk D, Hanke N, Wolf S, Frechen S, Eissing T, Wendl T, Schwab M, Lehr T. Physiologically based pharmacokinetic models for prediction of complex CYP2C8 and OATP1B1 (SLCO1B1) drug-drug-gene interactions: a modeling network of gemfibrozil, repaglinide, pioglitazone, rifampicin, clarithromycin and itraconazole. Clin Pharmacokinet 2019;58(12):1595-1607.
Moj D, Maas H, Schaeftlein A, Hanke N, Gómez-Mantilla JD, Lehr T. A comprehensive whole-body physiologically based pharmacokinetic model of dabigatran etexilate, dabigatran and dabigatran glucuronide in healthy adults and renally impaired patients. Clin Pharmacokinet 2019;58(12):1577-1593.
Hanke N, Kunz C, Thiemann M, Fricke H, Lehr T. Translational PBPK modeling of the protein therapeutic and CD95L inhibitor asunercept to develop dose recommendations for its first use in pediatric glioblastoma patients. Pharmaceutics 2019;11(4):152.
Britz H, Hanke N, Volz AK, Spigset O, Schwab M, Eissing T, Wendl T, Frechen S, Lehr T. PBPK models for CYP1A2 DDI prediction: a modelling network of fluvoxamine, theophylline, caffeine, rifampicin and midazolam. CPT Pharmacometrics Syst Pharmacol 2019;8(5):296-307.
Hanke N, Frechen S, Moj D, Britz H, Eissing T, Wendl T, Lehr T. PBPK models for CYP3A4 and P-gp DDI prediction: a modeling network for rifampicin, itraconazole, clarithromycin, midazolam, alfenatil and digoxin. CPT Pharmacometrics Syst Pharmacol 2018;7(10):647-659.
Scholl C, Lepper A, Lehr T, Hanke N, Schneider KL, Brockmöller J, Seufferlein T, Stingl JC. Population nutrikinetics of green tea extract. PLoS One 2018;13(2):e0193074.
Hanke N, Teifel M, Moj D, Wojtyniak JG, Britz H, Aicher B, Sindermann H, Ammer N, Lehr T. A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysis. Cancer Chemother Pharmacol 2018;81(2):291-304.
Moj D, Hanke N, Britz H, Frechen S, Kanacher T, Wendl T, Haefeli WE, Lehr T. Clarithromycin, Midazolam, and Digoxin: Application of PBPK modeling to gain new insights into drug-drug interactions and co-medication regimens. AAPS J 2017;19(1):298-312.
Kontakt
Dr. Nina Hanke
Klinische Pharmazie
Universität des Saarlandes
Campus C2 2, Zimmer 0.11
66123 Saarbrücken
T: +49/681/302-2484
F: +49/681/302-70258